HB 278, the "Longevity Ready Maryland Act," requires Maryland's Secretary of Aging to lead implementation of the Longevity Ready Maryland Plan. This plan aims to coordinate state services for older adults by evaluating their needs, assessing existing programs, and fostering cross-sector collaboration across health, housing, employment, and social services. The bill mandates annual reports to the governor and legislature on progress, updates the Commission on Aging's role, and requires a comprehensive statewide plan to be revised every four years. It directly affects older Marylanders, the Department of Aging, local area agencies on aging, and state agencies responsible for aging-related services.
SB 272 requires health insurance plans that cover chemotherapy for cancer treatment to also cover scalp cooling systems. These systems are devices designed to prevent or reduce hair loss during chemotherapy by cooling the scalp. The law applies to insurers, nonprofit health service plans, health maintenance organizations, and managed care organizations offering such coverage in Maryland. It takes effect for all policies issued, delivered, or renewed on or after January 1, 2027.
HB 393 requires health insurers, nonprofit health plans, HMOs, and managed care organizations in Maryland to cover scalp cooling systems when they provide coverage for chemotherapy treatments for cancer. This applies directly to cancer patients undergoing chemotherapy who use scalp cooling to prevent hair loss, and to the insurers that must now include this coverage. The bill defines scalp cooling systems as medical devices designed for repeated use to preserve hair during cancer treatment. Coverage must be provided for these systems as part of chemotherapy treatment plans, effective January 1, 2027. The law amends Maryland’s Insurance Article (Section 15-864) to mandate this coverage for qualifying health plans.
SB 385 (The Vax Act) requires Maryland’s Secretary of Health to issue evidence-based recommendations for immunizations, screenings, and preventive services, aligning with guidance from major medical organizations like the CDC and U.S. Preventive Services Task Force. It expands pharmacists’ authority to administer vaccines (including those recommended by CDC or the Secretary) to patients aged 3+ after completing specific training and certification, while mandating health insurers to cover these services without cost-sharing. The bill also repeals outdated pertussis-related provisions and updates reporting requirements for pharmacists. This directly affects pharmacists, health insurers, and patients seeking preventive care, aiming to improve access to vaccinations and screenings.
SB 333 creates the Interstate Podiatric Medical Licensure Compact, allowing podiatrists (foot and ankle specialists) licensed in Maryland to practice in other participating states more easily. The bill establishes a streamlined process for obtaining an "expedited license" in multiple states without altering existing state licensing laws, requiring podiatrists to pass national exams and pass background checks. Crucially, it mandates that podiatrists follow the rules of the state where the patient is located during treatment, not where the provider is licensed. This compact directly affects licensed podiatrists seeking multi-state practice and state licensing boards overseeing medical practice.
HB 637 ("The Vax Act") requires Maryland's Secretary of Health to issue science-based recommendations for immunizations, screenings, and preventive services using guidance from major medical organizations like the CDC and American Academy of Pediatrics. It expands pharmacists' authority to administer flu, COVID-19, and emergency vaccines to patients aged 3 and older (previously limited to 18+ for some vaccines) after completing specific training. The bill also mandates that health insurance plans cover these recommended services without cost-sharing for patients. This directly affects pharmacists, health insurers, and Maryland residents seeking preventive care, particularly children and adults needing routine vaccinations.
SB 444 repeals an exemption that previously allowed intermediate care facilities offering substance use disorder treatment to change bed capacity without a certificate of need. It creates a new exemption for facilities providing *medically managed residential substance use disorder treatment services*, removing the requirement for a certificate of need if they submit 45 days' written notice to the Commission and the Commission determines the change aligns with the state health plan, improves service efficiency, and serves the public interest. This bill directly affects intermediate care facilities focused on substance use disorder treatment by reducing regulatory barriers for expanding bed capacity or establishing new facilities. The key mechanism is replacing a certificate of need with a streamlined notice-and-review process administered by the Commission. (SB 444, "Certificate of Need - Intermediate Health Care Facilities," 2026)
HB 1445, the "Maryland Protecting People With Disabilities Act," changes eligibility rules for home- and community-based services under Maryland's Medicaid program (Maryland Medical Assistance Program). It requires the state to continue services uninterrupted during appeals if an individual loses eligibility, prohibits automatic termination solely due to administrative errors (procedural disenrollment), and mandates data sharing between providers and the Department of Health. The bill directly affects people receiving Developmental Disabilities Administration services and Medicaid beneficiaries who risk losing community-based care due to eligibility disputes. Key provisions include extending appeal timelines (replacing 90-day deadlines with continuous service until appeal resolution) and requiring the state to reserve waiver slots for those who lost eligibility unfairly. These changes aim to align with the Olmstead v. L.C. Supreme Court ruling protecting community integration rights.
This bill requires health insurers and health plans in Maryland to cover salpingectomy (surgery to remove fallopian tubes) specifically for ovarian cancer prevention as a standard benefit, with no out-of-pocket costs like copays or deductibles for patients. It applies to all health insurance policies issued in Maryland after January 1, 2027, directly affecting women who might choose this preventive surgery and the insurers providing coverage. The key provision bans cost-sharing for this procedure, except when an individual is enrolled in a high-deductible health plan meeting federal criteria. This ensures access to a proven preventive measure without financial barriers for most patients.
HB 797 prohibits employers from discriminating against fire and rescue public safety employees who use medical cannabis, provided they have a valid written certification from a licensed healthcare provider under Maryland's medical cannabis program. The bill modifies existing law to clarify that an employer cannot take adverse employment actions (like termination or denial of promotion) solely due to medical cannabis use, as long as the employee meets the state's certification requirements. It updates definitions in Maryland law to ensure fire and rescue employees qualify for the same protections as other medical cannabis patients under the existing program. The law does not override workplace safety rules or require employers to accommodate cannabis use during work hours.
